Literature DB >> 3689634

Oral phenytoin pharmacokinetics during omeprazole therapy.

P J Prichard1, R P Walt, G K Kitchingman, K W Somerville, M J Langman, J Williams, A Richens.   

Abstract

1. In a double-blind crossover study 10 healthy males received either placebo or omeprazole (40 mg day-1) for 9 days, a single dose of phenytoin (300 mg) being taken on the seventh day. 2. Omeprazole significantly increased the area under the curve (0 to 72 h) of phenytoin (mean +/- s.e. mean) from 121.6 +/- 14.0 to 151.4 +/- 13.6 micrograms ml-1 h) (P less than 0.01). 3. The peak concentration, and apparent elimination half-life of phenytoin also tended to be increased though not significantly. 4. The omeprazole-phenytoin interaction observed may be clinically important because of the low therapeutic index associated with phenytoin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689634      PMCID: PMC1386318          DOI: 10.1111/j.1365-2125.1987.tb03209.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers.

Authors:  P J Prichard; D Rubinstein; D B Jones; F J Dudley; R A Smallwood; W J Louis; N D Yeomans
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-23

2.  Effect of cimetidine on single-dose phenytoin kinetics.

Authors:  M O Iteogu; J E Murphy; N Shleifer; R Davis
Journal:  Clin Pharm       Date:  1983 Jul-Aug

Review 3.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

4.  The relationship between the binding of 2-n-alkylbenzimidazoles to rat hepatic microsomal cytochrome P-450 and the inhibition of monooxygenation.

Authors:  M Dickins; J W Bridges
Journal:  Biochem Pharmacol       Date:  1982-04-01       Impact factor: 5.858

5.  Omeprazole: effects on oxidative drug metabolism.

Authors:  D A Henry; K W Somerville; G Kitchingman; M J Langman
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

6.  The effects of sucralfate upon phenytoin absorption in man.

Authors:  H L Smart; K W Somerville; J Williams; A Richens; M J Langman
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

7.  Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

Authors:  R Gugler; J C Jensen
Journal:  Gastroenterology       Date:  1985-12       Impact factor: 22.682

  7 in total
  40 in total

1.  Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity.

Authors:  K A Bachmann; T J Sullivan; L Jauregui; J H Reese; K Miller; L Levine
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

Review 2.  Gastroenterology.

Authors:  L J O'Donnell; E M Alstead; M J Farthing
Journal:  Postgrad Med J       Date:  1990-06       Impact factor: 2.401

Review 3.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects.

Authors:  P A Soons; G van den Berg; M Danhof; P van Brummelen; J B Jansen; C B Lamers; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Omeprazole.

Authors:  M J Langman
Journal:  BMJ       Date:  1991-08-31

Review 6.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 8.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 9.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.